More about

Sitagliptin

News
January 17, 2025
2 min read
Save

Medicare selects 15 drugs for second round of price negotiations, including semaglutide

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

News
August 15, 2024
4 min read
Save

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

News
July 23, 2024
2 min read
Save

Semaglutide does not raise risk for neurologic disorders for adults with type 2 diabetes

Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.

News
October 03, 2022
5 min read
Save

GRADE: Insulin glargine, liraglutide better maintain glycemic control than other agents

Insulin glargine and the GLP-1 receptor agonist liraglutide are more effective at achieving an HbA1c of less than 7% than the sulfonylurea glimepiride or the DPP-IV inhibitor sitagliptin, according to data from the GRADE trial.

News
August 17, 2022
1 min read
Save

Top in endocrinology: Contaminated sitagliptin; added benefits of bariatric surgery

Although some samples of the antidiabetic drug sitagliptin may contain a human carcinogen called NTTP, the FDA said it hopes to avoid a shortage of the medication by temporarily allowing its distribution.

News
August 10, 2022
1 min read
Save

FDA: Possibly contaminated sitagliptin may be distributed to avoid shortage

The FDA announced it has learned that some samples of sitagliptin, used to treat type 2 diabetes, may contain a “nitrosamine impurity,” Nitroso-STG-19 or NTTP, which may be a human carcinogen.

News
June 29, 2021
4 min read
Save

GRADE: GLP-1 agonists, insulin more effective than other diabetes drugs

In a head-to-head study of four classes of glucose-lowering drugs, the GLP-1 receptor agonist liraglutide and insulin glargine were more effective for maintaining HbA1c below 7% than a sulfonylurea or DPP-IV inhibitor.

News
January 06, 2021
3 min read
Save

Sitagliptin may prevent acute GVHD after peripheral blood stem cell transplantation

Sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to phase 2 study results published in The New England Journal of Medicine.

News
December 02, 2020
1 min read
Save

Higher dose of sitagliptin does not increase risk for congestive heart failure in CKD

Researchers from Canada observed no link between higher doses of sitagliptin and increased risk for congestive heart failure in a cohort of patients older than 66 years who had both type 2 diabetes and chronic kidney disease.

News
October 01, 2020
2 min read
Save

Sitagliptin linked to lower mortality rate in adults with type 2 diabetes, COVID-19

Adults with type 2 diabetes who were hospitalized with COVID-19 in northern Italy had a lower mortality rate and better health outcomes when treated with the DPP-IV inhibitor sitagliptin, according to study data published in Diabetes Care.

View more